The vowst market research report is one of a series of new reports that provides vowst market statistics, including the vowst industry global market size, regional shares, competitors with the vowst market share, detailed vowst market segments, market trends, and opportunities, and any further data you may need to thrive in the vowst industry. This vowst market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing prevalence of inflammatory bowel diseases (IBD), increasing approval of diagnostics, prolonged consumption of antibiotics, increasing awareness of gut health, and rising incidence of chronic diseases. Major trends in the forecast period include growing acceptance of microbiota-based therapies, increased use of probiotics and prebiotics, shift toward personalized medicine, integration of artificial intelligence in research, and adoption of home healthcare solutions.
The growing prevalence of Clostridioides difficile infections (CDIs) is expected to drive the expansion of the Vowst market. These infections, caused by the bacterium Clostridioides difficile, typically result in colon inflammation, leading to symptoms such as severe diarrhea, abdominal pain, and fever. The rise in CDIs is influenced by factors such as the widespread use of antibiotics, which disrupt the gut microbiota, an increase in healthcare-associated infections, aging populations with weakened immune systems, and the emergence of more virulent strains of C. difficile. Vowst helps address these infections by restoring the natural balance of bacteria in the gut, which antibiotics often disrupt. For instance, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that in 2022, the overall incidence rate of CDI in the United States was 116.1 cases per 100,000 people. Of these, 62.1 cases per 100,000 were community-associated, while healthcare-associated cases accounted for 54 per 100,000. As a result, the increasing prevalence of CDI is contributing to the growth of the Vowst market.
A notable trend in the Vowst market is the development of innovative microbiome-based therapies aimed at treating recurrent Clostridioides difficile infections (rCDI). These specialized therapies are designed to target and eliminate C. difficile bacteria in patients who experience repeated infections, offering a promising solution to improve patient outcomes and prevent recurrence. For example, in April 2023, Seres Therapeutics, a U.S.-based biotech firm, and Nestlé Health Science, a Swiss pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Vowst, an orally administered microbiota-based therapeutic. Vowst is designed to prevent the recurrence of C. difficile infection in adults after initial antibacterial treatment for rCDI, working by restoring a healthy gut microbiome and reducing the likelihood of reinfection.
In August 2024, Nestlé Health Science acquired the Vowst business from Seres Therapeutics for $175 million. This acquisition is aimed at strengthening Nestlé’s position in the microbiome therapeutics field, particularly in treatments for gastrointestinal health. By bringing Vowst under its control, Nestlé Health Science enhances its portfolio of innovative therapies, including those focused on preventing recurrent C. difficile infections.
The key company operating in the vowst market is Seres Therapeutics Inc.
North America was the largest region in the vowst market in 2024. The regions covered in vowst report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vowst market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vowst is a prescription medication containing live fecal microbiota spores, designed to prevent the recurrence of Clostridioides difficile (C. diff) infections in adults following antibiotic treatment. It works by restoring beneficial gut bacteria, which helps inhibit C. diff's ability to proliferate and cause reinfection.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Vowst include infectious diseases, gut microbiota restoration, and immune modulation. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which invade the body and can spread either directly or indirectly among individuals. Vowst is distributed through various channels, including hospitals, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by a range of patients, including adults and geriatric individuals.
The vowst market consists of sales of vowst capsules, microbiome diagnostics kits, gut health supplements, and fecal microbiota transplant (FMT) alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing prevalence of inflammatory bowel diseases (IBD), increasing approval of diagnostics, prolonged consumption of antibiotics, increasing awareness of gut health, and rising incidence of chronic diseases. Major trends in the forecast period include growing acceptance of microbiota-based therapies, increased use of probiotics and prebiotics, shift toward personalized medicine, integration of artificial intelligence in research, and adoption of home healthcare solutions.
The growing prevalence of Clostridioides difficile infections (CDIs) is expected to drive the expansion of the Vowst market. These infections, caused by the bacterium Clostridioides difficile, typically result in colon inflammation, leading to symptoms such as severe diarrhea, abdominal pain, and fever. The rise in CDIs is influenced by factors such as the widespread use of antibiotics, which disrupt the gut microbiota, an increase in healthcare-associated infections, aging populations with weakened immune systems, and the emergence of more virulent strains of C. difficile. Vowst helps address these infections by restoring the natural balance of bacteria in the gut, which antibiotics often disrupt. For instance, in June 2024, the Centers for Disease Control and Prevention (CDC) reported that in 2022, the overall incidence rate of CDI in the United States was 116.1 cases per 100,000 people. Of these, 62.1 cases per 100,000 were community-associated, while healthcare-associated cases accounted for 54 per 100,000. As a result, the increasing prevalence of CDI is contributing to the growth of the Vowst market.
A notable trend in the Vowst market is the development of innovative microbiome-based therapies aimed at treating recurrent Clostridioides difficile infections (rCDI). These specialized therapies are designed to target and eliminate C. difficile bacteria in patients who experience repeated infections, offering a promising solution to improve patient outcomes and prevent recurrence. For example, in April 2023, Seres Therapeutics, a U.S.-based biotech firm, and Nestlé Health Science, a Swiss pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Vowst, an orally administered microbiota-based therapeutic. Vowst is designed to prevent the recurrence of C. difficile infection in adults after initial antibacterial treatment for rCDI, working by restoring a healthy gut microbiome and reducing the likelihood of reinfection.
In August 2024, Nestlé Health Science acquired the Vowst business from Seres Therapeutics for $175 million. This acquisition is aimed at strengthening Nestlé’s position in the microbiome therapeutics field, particularly in treatments for gastrointestinal health. By bringing Vowst under its control, Nestlé Health Science enhances its portfolio of innovative therapies, including those focused on preventing recurrent C. difficile infections.
The key company operating in the vowst market is Seres Therapeutics Inc.
North America was the largest region in the vowst market in 2024. The regions covered in vowst report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vowst market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vowst is a prescription medication containing live fecal microbiota spores, designed to prevent the recurrence of Clostridioides difficile (C. diff) infections in adults following antibiotic treatment. It works by restoring beneficial gut bacteria, which helps inhibit C. diff's ability to proliferate and cause reinfection.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for Vowst include infectious diseases, gut microbiota restoration, and immune modulation. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which invade the body and can spread either directly or indirectly among individuals. Vowst is distributed through various channels, including hospitals, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by a range of patients, including adults and geriatric individuals.
The vowst market consists of sales of vowst capsules, microbiome diagnostics kits, gut health supplements, and fecal microbiota transplant (FMT) alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vowst Market Characteristics4. Vowst Market Trends And Strategies5. Vowst Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vowst Pricing Analysis & Forecasts30. Global Vowst Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vowst Market32. Recent Developments In The Vowst Market
3. Vowst Market Biologic Drug Characteristics
6. Global Vowst Growth Analysis And Strategic Analysis Framework
8. Vowst Market Segmentation
9. Global Vowst Epidemiology Of Clinical Indications
10. Vowst Market Regional And Country Analysis
11. Asia-Pacific Vowst Market
12. China Vowst Market
13. India Vowst Market
14. Japan Vowst Market
15. Australia Vowst Market
16. South Korea Vowst Market
17. Western Europe Vowst Market
18. UK Vowst Market
19. Germany Vowst Market
20. France Vowst Market
21. Eastern Europe Vowst Market
22. North America Vowst Market
23. USA Vowst Market
24. Canada Vowst Market
25. South America Vowst Market
26. Middle East Vowst Market
27. Africa Vowst Market
28. Vowst Market Competitive Landscape And Company Profiles
29. Global Vowst Market Pipeline Analysis
33. Vowst Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vowst Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vowst market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vowst ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vowst market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Infectious Diseases; Gut Microbiota Restoration; Immune Modulation2) By Distribution Channel: Hospitals; Specialty Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
Key Companies Profiled: Seres Therapeutics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Seres Therapeutics Inc.